Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori

a multicentre, open-label, randomised trial

Jyh Ming Liou, Yu Jen Fang, Chieh Chang Chen, Ming Jong Bair, Chi Yang Chang, Yi Chia Lee, Mei Jyh Chen, Chien Chuan Chen, Cheng Hao Tseng, Yao Chun Hsu, Ji Yuh Lee, Tsung Hua Yang, Jiing Chyuan Luo, Chun Chao Chang, Chi Yi Chen, Po Yueh Chen, Chia Tung Shun, Wen Feng Hsu, Wen Hao Hu, Yen Nien Chen & 5 others Bor Shyang Sheu, Jaw Town Lin, Jeng Yih Wu, Emad M. El-Omar, Ming Shiang Wu

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. Methods In this multicentre, open-label, randomised trial, we recruited adult patients (aged >20 years) with H pylori infection from nine medical centres in Taiwan. Patients who had at least two positive tests from the rapid urease test, histology, culture, or serology or who had a single positive 13C-urea breath test for gastric cancer screening were eligible for enrolment. Patients were randomly assigned (1:1:1) to either concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily) for 10 days; bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day) for 10 days; or triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily) for 14 days. A computer-generated permuted block randomisation sequence with a block size of 6 was used for randomisation, and the sequence was concealed in an opaque envelope until the intervention was assigned. Investigators were masked to treatment allocation. The primary outcome was the eradication frequency of H pylori with first-line therapy assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01906879. Findings Between July 17, 2013, and April 20, 2016, 5454 patients were screened for eligibility. Of these, 1620 patients were randomly assigned in this study. The eradication frequencies were 90·4% (488/540 [95% CI 87·6–92·6]) for 10-day bismuth quadruple therapy, 85·9% (464/540 [82·7–88·6]) for 10-day concomitant therapy, and 83·7% (452/540 [80·4–86·6]) for 14-day triple therapy in the intention-to-treat analysis. 10-day bismuth quadruple therapy was superior to 14-day triple therapy (difference 6·7% [95% CI 2·7–10·7, p=0·001), but not 10-day concomitant therapy. 10-day concomitant therapy was not superior to 14-day triple therapy. The frequency of adverse events was 67% (358/533) in patients treated with 10-day bismuth quadruple therapy, 58% (309/535) in patients treated with 10-day concomitant therapy, and 47% (252/535) in patients treated with 14-day triple therapy. Interpretation Bismuth quadruple therapy is preferable to 14-day triple therapy in the first-line treatment in the face of rising prevalence of clarithromycin resistance. Concomitant therapy given for 10 days might not be optimum and a longer treatment length should be considered. Funding National Taiwan University Hospital and Ministry of Science and Technology of Taiwan.

Original languageEnglish
Pages (from-to)2355-2365
Number of pages11
JournalThe Lancet
Volume388
Issue number10058
DOIs
Publication statusPublished - Nov 12 2016

Fingerprint

Bismuth
Helicobacter pylori
Therapeutics
Lansoprazole
Clarithromycin
Pylorus
Taiwan
Amoxicillin
Metronidazole
Random Allocation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial. / Liou, Jyh Ming; Fang, Yu Jen; Chen, Chieh Chang; Bair, Ming Jong; Chang, Chi Yang; Lee, Yi Chia; Chen, Mei Jyh; Chen, Chien Chuan; Tseng, Cheng Hao; Hsu, Yao Chun; Lee, Ji Yuh; Yang, Tsung Hua; Luo, Jiing Chyuan; Chang, Chun Chao; Chen, Chi Yi; Chen, Po Yueh; Shun, Chia Tung; Hsu, Wen Feng; Hu, Wen Hao; Chen, Yen Nien; Sheu, Bor Shyang; Lin, Jaw Town; Wu, Jeng Yih; El-Omar, Emad M.; Wu, Ming Shiang.

In: The Lancet, Vol. 388, No. 10058, 12.11.2016, p. 2355-2365.

Research output: Contribution to journalArticle

Liou, JM, Fang, YJ, Chen, CC, Bair, MJ, Chang, CY, Lee, YC, Chen, MJ, Chen, CC, Tseng, CH, Hsu, YC, Lee, JY, Yang, TH, Luo, JC, Chang, CC, Chen, CY, Chen, PY, Shun, CT, Hsu, WF, Hu, WH, Chen, YN, Sheu, BS, Lin, JT, Wu, JY, El-Omar, EM & Wu, MS 2016, 'Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial', The Lancet, vol. 388, no. 10058, pp. 2355-2365. https://doi.org/10.1016/S0140-6736(16)31409-X
Liou, Jyh Ming ; Fang, Yu Jen ; Chen, Chieh Chang ; Bair, Ming Jong ; Chang, Chi Yang ; Lee, Yi Chia ; Chen, Mei Jyh ; Chen, Chien Chuan ; Tseng, Cheng Hao ; Hsu, Yao Chun ; Lee, Ji Yuh ; Yang, Tsung Hua ; Luo, Jiing Chyuan ; Chang, Chun Chao ; Chen, Chi Yi ; Chen, Po Yueh ; Shun, Chia Tung ; Hsu, Wen Feng ; Hu, Wen Hao ; Chen, Yen Nien ; Sheu, Bor Shyang ; Lin, Jaw Town ; Wu, Jeng Yih ; El-Omar, Emad M. ; Wu, Ming Shiang. / Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori : a multicentre, open-label, randomised trial. In: The Lancet. 2016 ; Vol. 388, No. 10058. pp. 2355-2365.
@article{7cd69cfc756d4638866014ce7c15daf7,
title = "Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial",
abstract = "Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. Methods In this multicentre, open-label, randomised trial, we recruited adult patients (aged >20 years) with H pylori infection from nine medical centres in Taiwan. Patients who had at least two positive tests from the rapid urease test, histology, culture, or serology or who had a single positive 13C-urea breath test for gastric cancer screening were eligible for enrolment. Patients were randomly assigned (1:1:1) to either concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily) for 10 days; bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day) for 10 days; or triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily) for 14 days. A computer-generated permuted block randomisation sequence with a block size of 6 was used for randomisation, and the sequence was concealed in an opaque envelope until the intervention was assigned. Investigators were masked to treatment allocation. The primary outcome was the eradication frequency of H pylori with first-line therapy assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01906879. Findings Between July 17, 2013, and April 20, 2016, 5454 patients were screened for eligibility. Of these, 1620 patients were randomly assigned in this study. The eradication frequencies were 90·4{\%} (488/540 [95{\%} CI 87·6–92·6]) for 10-day bismuth quadruple therapy, 85·9{\%} (464/540 [82·7–88·6]) for 10-day concomitant therapy, and 83·7{\%} (452/540 [80·4–86·6]) for 14-day triple therapy in the intention-to-treat analysis. 10-day bismuth quadruple therapy was superior to 14-day triple therapy (difference 6·7{\%} [95{\%} CI 2·7–10·7, p=0·001), but not 10-day concomitant therapy. 10-day concomitant therapy was not superior to 14-day triple therapy. The frequency of adverse events was 67{\%} (358/533) in patients treated with 10-day bismuth quadruple therapy, 58{\%} (309/535) in patients treated with 10-day concomitant therapy, and 47{\%} (252/535) in patients treated with 14-day triple therapy. Interpretation Bismuth quadruple therapy is preferable to 14-day triple therapy in the first-line treatment in the face of rising prevalence of clarithromycin resistance. Concomitant therapy given for 10 days might not be optimum and a longer treatment length should be considered. Funding National Taiwan University Hospital and Ministry of Science and Technology of Taiwan.",
author = "Liou, {Jyh Ming} and Fang, {Yu Jen} and Chen, {Chieh Chang} and Bair, {Ming Jong} and Chang, {Chi Yang} and Lee, {Yi Chia} and Chen, {Mei Jyh} and Chen, {Chien Chuan} and Tseng, {Cheng Hao} and Hsu, {Yao Chun} and Lee, {Ji Yuh} and Yang, {Tsung Hua} and Luo, {Jiing Chyuan} and Chang, {Chun Chao} and Chen, {Chi Yi} and Chen, {Po Yueh} and Shun, {Chia Tung} and Hsu, {Wen Feng} and Hu, {Wen Hao} and Chen, {Yen Nien} and Sheu, {Bor Shyang} and Lin, {Jaw Town} and Wu, {Jeng Yih} and El-Omar, {Emad M.} and Wu, {Ming Shiang}",
year = "2016",
month = "11",
day = "12",
doi = "10.1016/S0140-6736(16)31409-X",
language = "English",
volume = "388",
pages = "2355--2365",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10058",

}

TY - JOUR

T1 - Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori

T2 - a multicentre, open-label, randomised trial

AU - Liou, Jyh Ming

AU - Fang, Yu Jen

AU - Chen, Chieh Chang

AU - Bair, Ming Jong

AU - Chang, Chi Yang

AU - Lee, Yi Chia

AU - Chen, Mei Jyh

AU - Chen, Chien Chuan

AU - Tseng, Cheng Hao

AU - Hsu, Yao Chun

AU - Lee, Ji Yuh

AU - Yang, Tsung Hua

AU - Luo, Jiing Chyuan

AU - Chang, Chun Chao

AU - Chen, Chi Yi

AU - Chen, Po Yueh

AU - Shun, Chia Tung

AU - Hsu, Wen Feng

AU - Hu, Wen Hao

AU - Chen, Yen Nien

AU - Sheu, Bor Shyang

AU - Lin, Jaw Town

AU - Wu, Jeng Yih

AU - El-Omar, Emad M.

AU - Wu, Ming Shiang

PY - 2016/11/12

Y1 - 2016/11/12

N2 - Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. Methods In this multicentre, open-label, randomised trial, we recruited adult patients (aged >20 years) with H pylori infection from nine medical centres in Taiwan. Patients who had at least two positive tests from the rapid urease test, histology, culture, or serology or who had a single positive 13C-urea breath test for gastric cancer screening were eligible for enrolment. Patients were randomly assigned (1:1:1) to either concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily) for 10 days; bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day) for 10 days; or triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily) for 14 days. A computer-generated permuted block randomisation sequence with a block size of 6 was used for randomisation, and the sequence was concealed in an opaque envelope until the intervention was assigned. Investigators were masked to treatment allocation. The primary outcome was the eradication frequency of H pylori with first-line therapy assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01906879. Findings Between July 17, 2013, and April 20, 2016, 5454 patients were screened for eligibility. Of these, 1620 patients were randomly assigned in this study. The eradication frequencies were 90·4% (488/540 [95% CI 87·6–92·6]) for 10-day bismuth quadruple therapy, 85·9% (464/540 [82·7–88·6]) for 10-day concomitant therapy, and 83·7% (452/540 [80·4–86·6]) for 14-day triple therapy in the intention-to-treat analysis. 10-day bismuth quadruple therapy was superior to 14-day triple therapy (difference 6·7% [95% CI 2·7–10·7, p=0·001), but not 10-day concomitant therapy. 10-day concomitant therapy was not superior to 14-day triple therapy. The frequency of adverse events was 67% (358/533) in patients treated with 10-day bismuth quadruple therapy, 58% (309/535) in patients treated with 10-day concomitant therapy, and 47% (252/535) in patients treated with 14-day triple therapy. Interpretation Bismuth quadruple therapy is preferable to 14-day triple therapy in the first-line treatment in the face of rising prevalence of clarithromycin resistance. Concomitant therapy given for 10 days might not be optimum and a longer treatment length should be considered. Funding National Taiwan University Hospital and Ministry of Science and Technology of Taiwan.

AB - Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter pylori infection remains poorly understood. We aimed to compare the efficacy and safety of 10-day concomitant therapy, 10-day bismuth quadruple therapy, and 14-day triple therapy in the first-line treatment of H pylori. Methods In this multicentre, open-label, randomised trial, we recruited adult patients (aged >20 years) with H pylori infection from nine medical centres in Taiwan. Patients who had at least two positive tests from the rapid urease test, histology, culture, or serology or who had a single positive 13C-urea breath test for gastric cancer screening were eligible for enrolment. Patients were randomly assigned (1:1:1) to either concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily) for 10 days; bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day) for 10 days; or triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily) for 14 days. A computer-generated permuted block randomisation sequence with a block size of 6 was used for randomisation, and the sequence was concealed in an opaque envelope until the intervention was assigned. Investigators were masked to treatment allocation. The primary outcome was the eradication frequency of H pylori with first-line therapy assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01906879. Findings Between July 17, 2013, and April 20, 2016, 5454 patients were screened for eligibility. Of these, 1620 patients were randomly assigned in this study. The eradication frequencies were 90·4% (488/540 [95% CI 87·6–92·6]) for 10-day bismuth quadruple therapy, 85·9% (464/540 [82·7–88·6]) for 10-day concomitant therapy, and 83·7% (452/540 [80·4–86·6]) for 14-day triple therapy in the intention-to-treat analysis. 10-day bismuth quadruple therapy was superior to 14-day triple therapy (difference 6·7% [95% CI 2·7–10·7, p=0·001), but not 10-day concomitant therapy. 10-day concomitant therapy was not superior to 14-day triple therapy. The frequency of adverse events was 67% (358/533) in patients treated with 10-day bismuth quadruple therapy, 58% (309/535) in patients treated with 10-day concomitant therapy, and 47% (252/535) in patients treated with 14-day triple therapy. Interpretation Bismuth quadruple therapy is preferable to 14-day triple therapy in the first-line treatment in the face of rising prevalence of clarithromycin resistance. Concomitant therapy given for 10 days might not be optimum and a longer treatment length should be considered. Funding National Taiwan University Hospital and Ministry of Science and Technology of Taiwan.

UR - http://www.scopus.com/inward/record.url?scp=84994756793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994756793&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(16)31409-X

DO - 10.1016/S0140-6736(16)31409-X

M3 - Article

VL - 388

SP - 2355

EP - 2365

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10058

ER -